Last Posted: Aug 12, 2019
- Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.
Wu X, et al. Journal of clinical pharmacy and therapeutics 2018 6 (3) 408-413
- Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements.
Okamoto-Uchida Yoshimi, et al. Pharmacogenetics and genomics 2018 0 (3) 95-98
- Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population.
Tassaneeyakul Wichittra, et al. Pharmacogenetics and genomics 2016 5 (5) 225-34
- Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng Chau Yee, et al. The Journal of investigative dermatology 2016 0 (7) 1373-1381
- The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome.
Bellón Teresa, et al. Pharmacogenomics 2016 0 (6) 541-5
- Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population.
Jun Ikhyun, et al. The British journal of ophthalmology 2019 1
- Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications.
Ueta Mayumi, et al. Investigative ophthalmology & visual science 2018 11 (14) DES183-DES191
- Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.
Tangamornsuksan Wimonchat, et al. The pharmacogenomics journal 2018 9
- The UK guidelines for management and surveillance of Tuberous Sclerosis Complex.
Amin S et al. QJM : monthly journal of the Association of Physicians 2018 Sep
- A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine.
Ciccacci Cinzia, et al. The Journal of antimicrobial chemotherapy 2018 5
- Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand.
Jongkhajornpong Passara, et al. The British journal of ophthalmology 2018 4
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda Taisei, et al. JAMA neurology 2018 4
- Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.
Sukasem Chonlaphat, et al. Journal of immunology research 2018 0 2780272
- Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population.
Kannabiran Chitra, et al. Scientific reports 2017 11 (1) 15960
- Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype.
Yuliwulandari Rika, et al. Pharmacogenomics 2017 10
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Quick Links to Other Resources
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.